Evaluating T-cell response in patients with chronic kidney disease
Official title: Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic End-stage Kidney Disease Patients.
Run by Centre Hospitalier Régional d'Orléans · NCT06474169 · Data updated 2026-11-12
This study is trying to understand how the immune system works in patients with end-stage kidney disease to see if improving T-cell function can help reduce their risk of infections.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Centre Hospitalier Régional d'Orléans Academic / other |
| Drugs / interventions | Rituximab, Eculizumab |
| Locations | 1 site (Orléans) |
| Status | Recruiting |
| Started | November 27, 2024 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | June 25, 2026 |
| Trial ID | NCT06474169 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have been diagnosed with chronic kidney disease, particularly those at the end-stage.
✕Probably not a fit
Patients with chronic progressive infections, prior organ transplants, or those who have received immunosuppressive treatments in the last two years may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the immune response in patients suffering from chronic kidney disease, particularly focusing on those with end-stage kidney disease (ESKD). It seeks to define the immunodeficiency characteristics of T cells in these patients and provide an in-vitro proof-of-concept for T-cell engineering. By analyzing blood samples, the study will explore the relationship between T-cell function and the increased risk of infections in ESKD patients, which is a significant cause of mortality in this population.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of immune deficiencies in chronic kidney disease patients, potentially reducing infection-related complications.
How similar studies have gone: While the approach of assessing T-cell responses in ESKD is relatively novel, similar studies have shown promise in understanding immune responses in other chronic conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female ≥ 18 years 2. Informed participants who did not object to participating in the study Exclusion Criteria: 1. Chronic progressive infections 2. Prior organ transplantation (including bone marrow transplantation) 3. Previous treatment with immunosuppressive agents (such as Rituximab, Eculizumab, Tacrolimus or Ciclosporin, Cellcept or Imurel) within 2 years prior to inclusion 4. Participant under guardianship, curatorship or deprived of liberty 5. Pregnant or breastfeeding women
Where it's running
-
Center Hospitalier Universitaire d'Orléans
Orléans, France Recruiting
Study contacts
- Study coordinator: Manon DEKEYSER, PhD
- Email: manon.dekeyser@chu-orleans.fr
- Phone: +33238229870
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes
This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.
-
Impact of TAVR on kidney function in people with aortic valve disease
This registry tests how trans-catheter aortic valve implantation affects kidney function and the risk of kidney injury in adults with aortic stenosis.
-
Calciphylaxis in people with chronic kidney disease: causes, risks, and early signs
This project will compare adults with chronic kidney disease who develop calciphylaxis to matched CKD patients who do not, collecting clinical data and biological samples to try to find risk factors and early signs.
-
Oral Semaglutide for CKD and MAFLD in adults with diabetes
This study tests whether adding oral semaglutide to standard care can slow kidney and liver disease progression in adults with CKD and MAFLD who have type 2 diabetes.
-
Eye-brain-kidney connections in chronic kidney disease
This study will see if changes in brain network connectivity and retinal blood vessels are linked to cognitive decline and kidney function in adults with chronic kidney disease.
-
Screening for chronic kidney disease
We will see how common chronic kidney disease is among adults followed at a tertiary care center and how many cases were previously undiagnosed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.